



HAL
open science

Crystallization and Preliminary Crystallographic Data for Bovine Antithrombin III

J.P. Samama, M. Delarue, L. Mourey, J. Choay, D. Moras

► **To cite this version:**

J.P. Samama, M. Delarue, L. Mourey, J. Choay, D. Moras. Crystallization and Preliminary Crystallographic Data for Bovine Antithrombin III. *Journal of Molecular Biology*, 1989, 210 (4), pp.877-879. 10.1016/0022-2836(89)90116-2 . hal-03004885

HAL Id: hal-03004885

<https://cnrs.hal.science/hal-03004885v1>

Submitted on 20 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Crystallization and Preliminary Crystallographic Data for Bovine Antithrombin III

Crystals of bovine antithrombin III were obtained in the presence of metal ions with ammonium sulphate as precipitating agent. Crystals belong to space group $P4_12_12$ or $P4_32_12$ with cell parameters $a=b=91.4 \text{ \AA}$, $c=383.1 \text{ \AA}$; there are two molecules per asymmetric unit. Electrophoresis experiments and amino acid sequence analysis of the N-terminal part of redissolved crystals suggest that the protein molecules are cleaved at the active site.

Bovine antithrombin III (ATIII \dagger) is a single chain glycoprotein of molecular weight 56,600 (Kurachi *et al.*, 1976). Abundant in blood serum, antithrombin III inhibits primarily serine proteases of the blood coagulation pathway, such as factors IXa, Xa and XIa (Rosenberg, 1977) and thrombin, which, from consideration of relative rates of inactivation, is thought to be its principal physiological target (Travis & Salvensen, 1983).

Inhibition of serine proteases was shown to occur through the formation of a 1:1 stable complex of enzyme and inhibitor (Damus *et al.*, 1973). The rate of inactivation of thrombin by ATIII is enhanced by four orders of magnitude upon binding of a polysaccharide, heparin (Jordan *et al.*, 1980; Hoylaerts *et al.*, 1984). When this tight complex is dissociated, the bovine ATIII molecule is found to be cleaved at a specific peptide bond: Arg393-Ser394 (Jörnvald *et al.*, 1979). This cleaved molecule (AT_M), made of two fragments (M_r 50,000 and 5000) held together by a disulphide bridge, has no detectable protease-inhibiting activity (Björk & Fish, 1982).

Antithrombin III is a member of the serpin superfamily (Carrell & Boswell, 1986), which includes inhibitors of serine proteases as well as ovalbumin (Hunt & Dayhoff, 1980) of no known anti-protease activity. Sequence alignments within this family led to the hypothesis that these proteins have evolved from an ancestral serine proteinase inhibitor. The N-terminal parts of these proteins show significant variation in length. In the case of human antithrombin III, it has been shown that Pro41 (Chang & Tran, 1986), Arg47 (Koide *et al.*, 1984), Trp49 (Blackburn *et al.*, 1984) and Lys125 (Peterson *et al.*, 1987) are essential for heparin binding and activation of the inhibitor. *A contrario*, the antithrombin III molecule deprived of its carbohydrate at Asn135 was shown to display a higher affinity to heparin (Brennan *et al.*, 1987).

The X-ray structure analysis of ATIII was undertaken in order to provide a molecular description of

the heparin and thrombin binding sites. From a topological view point, it will also be interesting to compare the antithrombin III structure with that of the cleaved and homologous α -1 antitrypsin molecule (Loebermann *et al.*, 1984).

Antithrombin III was purified from bovine plasma by affinity chromatography on heparin-Sepharose. The protein displayed normal activity against thrombin. Crystals were obtained by the microdialysis method (Zeppezauer *et al.*, 1968) at 4°C. A solution of protein (13 mg/ml) in 80 mM-phosphate buffer (pH 6.2) was equilibrated by batch dialysis against the same buffer containing 1 mM-cadmium chloride and ammonium sulphate at 20% saturation. The protein solution was limp, although the dialysis medium displayed some turbidity, indicating possible cadmium uptake by the protein. The protein solution was then microdialysed against the same medium containing 50% saturated ammonium sulphate. After one week, the ammonium sulphate concentration was increased to 70% saturation. Crystals appeared within three weeks as cubes of 0.3 mm \times 0.3 mm \times 0.3 mm. Crystals were also grown in the presence of mercuric or zinc divalent ions in order to derive phase information if the cations proved to be located at specific binding positions.

The crystals were analysed using X-ray synchrotron sources at LURE (Orsay, France) and CHESS (Cornell University, Ithaca, NY, U.S.A.). Symmetry of the diffraction patterns and the specific extinction coefficients are consistent with the tetragonal space groups $P4_32_12$ or $P4_12_12$. The cell parameters are: $a=b=91.4 \text{ \AA}$, $c=383.1 \text{ \AA}$ ($1 \text{ \AA}=0.1 \text{ nm}$). The asymmetric unit contains two molecules of ATIII which give a crystal volume per unit of molecular weight of $3.6 \text{ \AA}^3/\text{dalton}$ and a V/Z value of $2 \times 10^5 \text{ \AA}^3$, close to that found for α -1 anti-trypsin (Loebermann *et al.*, 1984). This value is in agreement with the molecular replacement analysis. Crystals are very stable under X-ray exposure and up to 20° oscillation could be collected on the same crystal. The diffraction limit is 3.0 Å. Complete data sets to 3.5 Å were collected for crystals grown in the presence of CdCl₂, HgCl₂ or

\dagger Abbreviations used: ATIII, bovine antithrombin III; AT_M, cleaved antithrombin.

ZnCl₂ and 70% of the complete data set to 3.0 Å are available. High-resolution data collection is underway. One heavy-atom derivative was prepared by soaking native crystals in a 2 mM solution of PtCl₄ for three days. This derivative was isomorphous to the native data to 5 Å resolution. Native crystals were soaked with a solution of the pentasaccharide molecule (Choay *et al.*, 1983), which represents the shortest heparin fragment active with respect to inhibition of factor Xa. The corresponding diffraction data (80% complete at 3.5 Å resolution) are isomorphous to the native data to 4.0 Å resolution.

Biochemical analyses were performed in order to check the molecular species present in the crystals. These were washed twice in concentrated ammonium sulphate, and after careful drying, dissolved in water. SDS/polyacrylamide gel electrophoresis under reducing conditions revealed a major band corresponding to AT_M. Control of supernatant mother liquor showed two bands: the major one corresponded to native ATIII, the second band to AT_M of smaller molecular weight. While the biological activity of the protein in the mother liquor was still measurable, there was no detectable activity in redissolved crystals. Moreover, amino acid analysis of the N-terminal part indicated the presence of two N termini: one corresponds to the known sequence of the bovine protein (Kurachi *et al.*, 1976) and the second begins at Leu395 (human ATIII numbering), one amino acid away from the cleavage site. Their respective amounts agree, within the limits of error, to the expected ratio of N-termini species. It seems that AT_M fractionates itself out of the solution by crystallizing preferentially. The fact that the mother liquor still displays activity is not in favour of a continuous breakdown during crystallization. This residual activity cannot be easily quantified due to the presence of cadmium ions used for the crystallization of the protein which were shown to affect antithrombin III activity in fresh preparations. It should also be mentioned that crystallization of antithrombin III is dependent upon protein batches. One reason might be the microheterogeneity brought about by the four oligosaccharide chains, which is clearly seen on isoelectrofocusing gel analysis. The variability in crystallization behaviour may be related to this heterogeneity if some of the oligosaccharide chains are involved in the crystal packing of the molecules. Several crystallization experiments using modified antithrombin III species are currently underway.

Structure determination of antithrombin III is currently being pursued using the isomorphous replacement method and the molecular replacement techniques with α -1 antitrypsin tridimensional structure (30% sequence homology with the human protein) as a model. A clear signal in the cross rotation function is consistent with two molecules of antithrombin III per asymmetric unit. This might reflect conservation of the core in the three-dimensional structure of these two members of the serpin family.

From a functional viewpoint, there is still a major interest in the structure determination of antithrombin III, particularly the description of the heparin binding site, which seems very similar within antithrombin III of different origins (Gettins, 1987) and homologous to the one of the histidine-rich glycoprotein (Koide *et al.*, 1986).

We thank Dr Petitou and Lormeau (Institut Choay) for stimulating discussions. Mr Maman and Dr Piemont (Faculté de Médecine, Strasbourg) for biochemical analysis, Dr Reinbold and Dr Mejdoub (IBMC, Strasbourg) for amino acid sequencing and the staff from the glassware workshop at the Institut de Chimie in Strasbourg for facilities placed at our disposal. We also thank the stalls of LURE (Orsay, France) and CHESS (Ithaca, U.S.A.) for excellent data collection facilities.

J. P. Samama¹
M. Delarue¹
L. Mourey¹
J. Choay²
D. Moras¹

¹Laboratoire de Cristallographie Biologique,
I.B.M.C. du C.N.R.S.

15 rue René Descartes, 67000 Strasbourg, France

²Institut Choay, 46 Av. Théophile Gautier
75782 Paris Cedex France

Received 10 July 1989, and in revised form
7 August 1989.

References

- Björk, I. & Fish, W. W. (1982). *J. Biol. Chem.* **257**, 9487–9493.
- Blackburn, M. N., Smith, R. L., Carson, J. & Sibley, C. C. (1984). *J. Biol. Chem.* **259**, 939–941.
- Brennan, S. O., George, P. M. & Jordan, R. E. (1987). *FEBS Letters*, **219**, 431–436.
- Carrell, R. W. & Boswell, D. R. (1986). In *Proteinase Inhibitors* (Barrett & Salvesen, eds), pp. 403–420. Elsevier Science Publishers BV, Amsterdam.
- Chang, J.-Y. & Tran, T. H. (1986). *J. Biol. Chem.* **261**, 1174–1176.
- Choay, J., Petitou, M., Lormeau, J. C., Sinay, P., Casu, B. & Gatti, G. (1983). *Biochem. Biophys. Res. Commun.* **116**, 492–499.
- Damus, P. S., Hicks, M. & Rosenberg, R. D. (1973). *Nature (London)*, **246**, 355–357.
- Gettins, P. (1987). *Biochemistry*, **26**, 1391–1398.
- Hoylaerts, M., Owen, W. G. & Collen, D. (1984). *J. Biol. Chem.* **259**, 5670–5677.
- Hunt, L. T. & Dayhoff, M. O. (1980). *Biochem. Biophys. Res. Commun.* **95**, 864–871.
- Jordan, R. E., Oosta, G. M., Gardner, W. T. & Rosenberg, R. D. (1980). *J. Biol. Chem.* **255**, 10081–10090.
- Jörnvall, H., Fish, W. W. & Björk, I. (1979). *FEBS Letters*, **106**, 358–362.
- Koide, T., Odani, S., Takahashi, K., Ono, T. & Sakuragawa, N. (1984). *Proc. Nat. Acad. Sci., U.S.A.* **81**, 289–293.
- Koide, T., Foster, D. & Odani, S. (1986). *FEBS Letters*, **194**, 242–244.

- Kurachi, K., Schmer, G., Hermodson, M. A. Teller, D. C. & Davie, E. W. (1976). *Biochemistry*, **15**, 368-372.
- Loebermann, H., Tokuoka, R., Diesenhofer, J. & Hubert, R. (1984). *J. Mol. Biol.* **177**, 531-556.
- Peterson, C. B., Noyes, C. M., Pecon, J. M., Church, F. C. & Blackburn, M. N. (1987). *J. Biol. Chem.* **262**, 8061-8065.
- Rosenberg, R. D. (1977). *Fed. Proc. Fed. Amer. Soc. Exp. Biol.* **36**, 10-18.
- Travis, J. & Salvensen, G. S. (1983). *Annu. Rev. Biochem.* **52**, 655-709.
- Zeppezauer, M., Eklund, H. & Zeppezauer, E. S. (1968). *Arch. Biochem. Biophys.* **126**, 564.

Edited by R. Huber